A 2022 literature survey of younger patients (median age of 44 years with a range from 20 to 65 years) with no comorbid conditions and ND-AML found that the FLAG-Ida induction protocol benefits from the addition of a BH-3 mimetic, such as venetoclax [6]. Here, IDUA is linked to acute myeloid leukemia.